search button
Open Access

Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT‑III: A pilot study

  • Authors:
    • Lihua Zhang
    • Haitao Zhang
    • Jiong Zhang
    • Hong Tian
    • Ju Liang
    • Zhihong Liu

  • View Affiliations

  • Published online on: November 8, 2017     https://doi.org/10.3892/etm.2017.5471
  • Pages: 739-744

  • Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The anticoagulation effect of heparin requires adequate serum antithrombin (AT)‑III levels. Rivaroxaban, however, exhibits its anticoagulation effects independent of AT‑III. The aim of the present study was to evaluate the efficacy and safety of rivaroxaban as a treatment for venous thromboembolism in patients with AT‑III deficiency due to nephrotic syndrome. Patients with nephrotic syndrome and low serum concentration and functional activity of AT‑III and venous thromboembolism were randomly assigned to the rivaroxaban group (n=8) and low weight molecular heparin group (n=8). The patients were treated for 4 weeks and evaluated at weeks 2 and 4. The primary endpoint was thrombus dissolution or a >90% decrease in thrombus volume in 4 weeks. Secondary endpoints included an increase in the volume of the pre‑existing thrombosis and safety assessments. In each of the two groups, 7/8 patients achieved a primary endpoint. At week 2, 5 patients in the rivaroxaban group and 4 in the low weight molecular heparin group had achieved the primary endpoint. Notably, at week 2 the patients whose AT‑III levels and functional activity remained low in the low weight molecular heparin group did not achieve the primary endpoint. The adverse effects were similar in both groups, with no severe hemorrhage observed. In conclusion, the results of this pilot study demonstrate that rivaroxaban may be an effective, safe, single‑agent approach for treating vein thromboembolism in patients with nephrotic syndrome and low AT‑III levels. The potential benefits of rivaroxaban over low weight molecular heparin treatment require further investigation with a larger sample size in order to validate the findings of the present study.
View Figures
View References

Related Articles

Journal Cover

January-2018
Volume 15 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.7
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Zhang L, Zhang H, Zhang J, Tian H, Liang J and Liu Z: Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT‑III: A pilot study. Exp Ther Med 15: 739-744, 2018
APA
Zhang, L., Zhang, H., Zhang, J., Tian, H., Liang, J., & Liu, Z. (2018). Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT‑III: A pilot study. Experimental and Therapeutic Medicine, 15, 739-744. https://doi.org/10.3892/etm.2017.5471
MLA
Zhang, L., Zhang, H., Zhang, J., Tian, H., Liang, J., Liu, Z."Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT‑III: A pilot study". Experimental and Therapeutic Medicine 15.1 (2018): 739-744.
Chicago
Zhang, L., Zhang, H., Zhang, J., Tian, H., Liang, J., Liu, Z."Rivaroxaban for the treatment of venous thromboembolism in patients with nephrotic syndrome and low AT‑III: A pilot study". Experimental and Therapeutic Medicine 15, no. 1 (2018): 739-744. https://doi.org/10.3892/etm.2017.5471